Novel Therapies for Eosinophilic Disorders

Bruce S. Bochner*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


Current therapies for eosinophilic disorders are limited. Most treatment approaches remain empirical, are not supported by data from controlled clinical trials, involve the off-label use of agents developed for treatment of other diseases, and tend to rely heavily on the use of glucocorticoids and other agents with significant toxicity. Great progress has been made in the discovery, preclinical development, and clinical testing of a variety of biologics and small molecules that have the potential to directly or indirectly influence eosinophils, eosinophilic inflammation, and the consequences of eosinophil activation.

Original languageEnglish (US)
Pages (from-to)577-598
Number of pages22
JournalImmunology and Allergy Clinics of North America
Issue number3
StatePublished - Aug 1 2015


  • Antibodies
  • Biomarkers
  • Eosinophil
  • Pharmacology
  • Targets
  • Therapies

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Novel Therapies for Eosinophilic Disorders'. Together they form a unique fingerprint.

Cite this